Italy's Amplifon 9M profit rises helped by operating leverage and the Fit4Growth program

Overview

• Italy hearing care provider's first nine months revenue grew 0.9% yr/yr to EUR 1.76 bln

• Adjusted EBITDA for first nine months up 4.5%, margin improved

• Adjusted EBIT up 11.5% and adjusted net profit up 16.9% yr/yr

Outlook

• Amplifon confirms 2026 outlook for organic growth above 3%

• Company expects adjusted EBITDA margin to rise about 100 bps in 2026

Result Drivers

• ORGANIC GROWTH - Co said revenue growth was mainly driven by organic growth across all regions

• OPERATING LEVERAGE - Co attributed profitability gains to operating leverage and Fit4Growth program

• ACQUISITIONS IMPACT - Acquisitions contributed modestly to revenue growth, while network optimization offset some gains

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Amplifon SpA is €14.00, about 8.1% above its October 28 closing price of €12.96

• The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads

• Oct 29 - Europe Inc heads for second-best earnings season since 2022

• Oct 28 - Campari confirms 2026 outlook after 3.4% rise in third quarter revenue

• Oct 28 - Unilever tops Q3 sales estimates, raises dividend

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)